Blood cancer prevalence in population or why everyone should have a full blood examination test yearly.
Some countries with the most advanced healthcare systems made all their people have a blood test yearly. One of the tests is a Full Blood Examination.
The reason for this relatively cheap but effective health monitoring routine was that many people live with blood cancer without knowing it. The symptoms of blood cancer appear, sometimes, years after the disease set in. If not treated, a person with blood cancer dies from a relatively simple infection. Sadly, only then do doctors find out that the person dying from a common cold had blood cancer!
An estimated 9.8% of the population or one in ten people will suffer from blood cancer at some stage in their life. Most of those people will die. Astonishingly, if all those people had a yearly blood test, they would be treated early and, most likely, survive.
Unfortunately, full blood examination is not allowed under Medicare without symptoms. In other words, until you FEEL SICK, your GP will not be allowed to order a full blood examination or most of any other tests, for that matter. Government-funded blood tests are mostly allowed only when a person is already ill.
Luckily, there is a solution. People can order their tests themselves! That includes a Full blood examination test. With DEXANOVA it is an affordable easy test that can be repeated every year. The results of the test are stored on a secure individual portal for a long term follow up.
- The Leukemia & Lymphoma Society (LLS). https://www.lls.org/facts-and-statistics/facts-and-statistics-overview#:~:text=General%20Blood%20Cancers,-New%20Cases&text=An%20estimated%20combined%20total%20of,in%20the%20US%20in%202021. Last accessed 27.10.2021
- https://evidence.nihr.ac.uk/alert/results-from-a-routine-blood-test-could-help-in-early-detection-of-cancer/. Last accessed 27.10.2021
- The full paper: Mounce L, and others. Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care. British Journal of General Practice, 2020;70: e622-e628.
- A paper by the same researchers had earlier established raised platelet count as a risk marker for cancer. Bailey SER, and others. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. British Journal of General Practice, 2017;67: e405-e413.
- NICE guideline: Suspected cancer: recognition and referral. NG12. London: NICE, 2017
- Ankus E and others. Cancer incidence in patients with a high normal platelet count: a cohort study using primary care data. Fam Pract 2018; 35: 671–675.